linjc16/ctgov huggingface dataset:
Measuring Quality of Decisions About Treatment of Menopausal Symptoms

Study Overview
=================
Brief Summary
-----------------
The purpose of this randomized controlled trial is to examine the impact of a patient decision aid on the quality of decisions about managing symptoms of menopause. In particular, we will examine whether the decision aid increases knowledge about menopause/managing menopause symptoms and concordance between goals and treatment choices.

Official Title
-----------------
Measuring Quality of Decisions About Treatment of Menopausal Symptoms

Conditions
-----------------
Menopause

Intervention / Treatment
-----------------
* Behavioral: DVD & Booklet called: Managing Menopause


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female, aged 40-60 Talked with health care provider about ways to manage menopause within last year OR seriously considered taking medicine or supplement to manage menopause within the last year Exclusion Criteria: Prior diagnosis of breast cancer Surgical or medically induced menopause (ovaries removed)

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Group not receiving the decision aid (DVD and booklet) | |
| Experimental: Decision Aid<br>Group receiving the decision aid (DVD/booklet) | Behavioral: DVD & Booklet called: Managing Menopause<br>* DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms<br>* Other names: Shared decision making programs;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Menopause Knowledge | Total knowledge score from factual questions about menopause and methods for managing menopause symptoms. Score is the percent of knowledge questions answered correctly (0 - 100%) | 2 weeks, on average | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Value Concordance | Measure of how concordant respondents' actual decisions about treatment for their menopause symptoms are with their stated beliefs | 2 weeks, on average | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Menopause, Decision making, Decision aids, Decision quality instrument
Wolff-Parkinson-White Syndrome Anterograde Refractory Period of Accessory Duct

Study Overview
=================
Brief Summary
-----------------
The study consists of the realization of a new esophageal stimulation for patients already stimulated 10 years ago. The investigators would like to make a long term evaluation of the evolution of anterograde effective refractory period of accessory duct in the WPW syndrome. This study will be realized by esophageal stimulation.

Official Title
-----------------
Long Term Evolution of the Anterograde Refractory Period of Accessory Duct in the Wolff-Parkinson-White Syndrome

Conditions
-----------------
Wolff-Parkinson-White Syndrome

Intervention / Treatment
-----------------
* Procedure: esophagal stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 21 < age < 64 years First esophagal stimulation with evaluation of effective anterograde refractory period > 10 years Informed consent signed Diagnosis of Wolff-Parkinson-White syndrome No procedure of ablation of accessory duct Exclusion Criteria: Ablation of accessory duct Patient with contraindication to esophageal stimulation Patient with contraindication to effort test

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Stimulation<br>All patients included have the stimulation | Procedure: esophagal stimulation<br>* ECG (rest) esophagal stimulation (rest and during effort)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of effective anterograde refractory period of accessory duct and its evolution for a follow up superior to 10 years |  | Day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Triggering a supra-ventricular tachycardia during the stimulation. |  | Day 0 | 
| Presence of symptoms linked to WPW syndrome during the interval separating the 2 esophageal stimulation. |  | Day 0 |
Goal Directed Therapy for Acute Kidney Injury in Critical Ill Patients

Study Overview
=================
Brief Summary
-----------------
Acute kidney injury (AKI) is a frequent complication in critically ill patients admitted to intensive care unit (ICU) and it is associated with increased morbimortality. There is evidence that perioperative hemodynamic optimization decreases the incidence of AKI in the post operative phase in high-risk patients. We aimed to evaluate if the use of a goal-directed therapy to increase oxygen delivery in the early phase of acute kidney injury can decrease the prevalence of patients with acute renal failure.

Detailed Description
-----------------
Randomized, controlled, multicenter study.The intervention group was monitored with Flo Trac/Vigileo and optimized with fluid challenges, dobutamine and blood transfusion, if necessary, to maintain a IDO² ≥600ml/min/m² during 8h. The control group was treated according to the discretion of the attending physician.

Official Title
-----------------
Goal Directed Therapy in the Early Phase of Acute Kidney Injury in Critical Ill Patients

Conditions
-----------------
Acute Kidney Injury

Intervention / Treatment
-----------------
* Other: Goal-directed therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted in the Intensive Care Unit with Acute Kidney Injury (AKI) classified as AKIN 1 (increase in serum creatinine ≥0.3 mg/dL and/or urine output less than 0.5 ml/kg/h over 6 hours) for less than 12 hours. Exclusion Criteria: ICU length of stay >10 days, nefrectomy, chronic kidney disease undergoing hemodialysis, baseline creatinine ≥4 mg/dL, life expectance ≤ than 1 month, pregnancy, severe arrhythmia, severe heart failure (≤ III, NYHA), acute myocardial infarction (AMI)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention group<br>Goal-directed therapy | Other: Goal-directed therapy<br>* Goal-directed therapy with fluids and dobutamine<br>* Other names: Protocol of ressuscitation;|
| No Intervention: Control group<br>Control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acute kidney injury |  | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Goal Directed Therapy, Acute Kidney Injury
SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that children are less likely to become infected in the school environment, compared to the household or outside the school setting. Primary schools do not play a major role in SARS-CoV-2 spreading. They hypothesize that incidence level in schools is mainly a consequence of community transmission. The incidence level in household and that the secondary attack rate in schools remains at least 5 times lower that the transmission level in households.

Official Title
-----------------
SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study

Conditions
-----------------
SARS-CoV-2 Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All children and school attenders from selected schools was invited to participate Exclusion Criteria: Refusal to provide written informed consent before enrolment

Ages Eligible for Study
-----------------
Minimum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infection of a child with SARS-CoV-2 secondary to a classmate | Time varying number and proportion of children infected with SARS-CoV-2 secondary to an asymptomatic infected classmate (transmission rate inside school with the child being the infector). | 6 weeks | 
| Infection of an adult school-attender with SARS-CoV-2 secondary to an infected child | Time varying number and proportion of adult school-attenders infected with SARS-CoV-2 secondary to an asymptomatic infected child (transmission rate inside school but from a child to an adult). | 6 weeks | 
| Infection of a child with SARS-CoV-2 secondary to an adult school attender | Time varying number and proportion of children infected with SARS-CoV-2 secondary to an infected adult school-attender (transmission rate inside school but from an adult to a child) | 6 weeks | 
| Infection of a child with SARS-CoV-2 secondary to a contact outside the school, including the household | Time varying number and proportion of children infected with SARS-CoV-2 secondary to a household contact or outside the school (transmission rate from in community). | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Primary Schools
Kinematics of Youth (Age 12-15) on Stationary All Terrain Vehicles

Study Overview
=================
Brief Summary
-----------------
To assess the relationship between pre-teen/teen height, age, weight, gender, and body proportions and shape and size of youth and comfort and safety when operating adult All Terrain Vehicles (ATV).

Official Title
-----------------
Kinematics of Youth (Age 12-15) on Stationary All Terrain Vehicles

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: males age 12-15 a minimum level of physical skill to mount and dismount the vehicle ability to speak and understand English. We have used this age group because it is the most often injured group and represents an entire age group for ATV size restriction (other age groups not studied here are 6-11, and 16 or greater). Exclusion Criteria: inability to participate in physical education without restrictions visual acuity < 20/40 corrected females emancipated minors. We have excluded females to gain the most consistent body dimensions in this preliminary study.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantify relationship of youth size/shape to comfort and safety when operating adult ATV |  | 1 session | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Normal, Healthy Volunteers
Verisee Software for Diabetic Retinopathy Screening

Study Overview
=================
Brief Summary
-----------------
The investigators aim to improve the diagnostic accuracy and the clinical referral rate for diabetic retinopathy by using a deep learning-based software.

Detailed Description
-----------------
Diabetic retinopathy (DR) is the leading cause of blindness among working-age patients with type 2 diabetes. According to previous studies, early screening and timely treatment can reduce the risk of worsening DR and blindness. International guidelines recommend that screening for DR be performed at least once every year for patients with type 2 diabetes. The investigators will implement a validated deep learning-based software, VeriSee®, in clinics, and evaluate the benefits on diagnostic accuracy and the clinical referral rate for diabetic retinopathy after implementation of this software.

Official Title
-----------------
The Clinical Benefit of an Artificial Intelligence Software Implementation on Diabetic Retinopathy Screening

Conditions
-----------------
Diabetic Retinopathy

Intervention / Treatment
-----------------
* Device: VeriSee®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults Patients with diabetes Cooperation to fundal scopic examination Exclusion Criteria: Diabetic duration < 5 years in patients with type 1 diabetes Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Interventional Model Description: Examine the diagnostic accuracy in referred participants
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Verisee<br>Screening diabetic retinopathy using Verisee software | Device: VeriSee®<br>* Screening of diabetic retinopathy using a validated deep learning-based software,VeriSee®<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnostic accuracy | diagnostic accuracy compared to the baseline | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Screening rate of diabetic retinopathy | Screening rate of diabetic retinopathy in patients with diabetes | 12 months | 
| Changes in HbA1c | Changes in HbA1c | 3 months | 
| Referral rate of diabetic retinopathy | Successful referral rate for referrable diabetic retinopathy | 12 months |
Text Messaging for Adherence in Adolescent Liver Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
Text message reminders will improve adherence to lab tests in adolescent liver transplant recipients.

Detailed Description
-----------------
Adolescent patients who received a liver transplant will be recruited to participate in receiving text message reminders for lab tests. They will be send de-identified messages according to their required lab schedule. The investigators will monitor their adherence to lab tests as well as medication and clinic visits. They will also have a questionnaire about their medical regimen before and at the end of the study.

Official Title
-----------------
Impact of Text Messaging on Adherence in Adolescent Liver Transplant Patients

Conditions
-----------------
Liver Transplant, Adherence

Intervention / Treatment
-----------------
* Behavioral: Text Message Reminder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient >12 years Received liver transplant Followed by Stanford Liver Transplant Team Exclusion Criteria: No personal cell phone

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Text Message Reminder<br> | Behavioral: Text Message Reminder<br>* Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence to lab tests |  | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Texting responses | Correspondence between actual completion of tests versus reported | 1 year |
The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS

Study Overview
=================
Brief Summary
-----------------
To determine the effect of methylprednisolone on respiratory failure in HIV-infected patients with presumed or confirmed pneumocystis carinii pneumonia who are stratified for presence or absence of respiratory failure at the time of randomization to the study.

Detailed Description
-----------------
HIV-infected children are randomized to receive adjunctive therapy with intravenous methylprednisolone or placebo. Treatment is administered for 10 days. Primary antipneumocystis therapy with TMP/SMX or systemic pentamidine is selected by the individual investigator and given for 21 days. Patients are stratified at the time of randomization by the presence or absence of respiratory failure.

Official Title
-----------------
A Controlled Randomized Trial to Study the Efficacy of Adjunctive Methylprednisolone for the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Pediatric AIDS Patients

Conditions
-----------------
Pneumonia, Pneumocystis Carinii, HIV Infections

Intervention / Treatment
-----------------
* Drug: Methylprednisolone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Allowed: Recombinant erythropoietin and any FDA-approved cytokine for management of anemia. Antiretroviral agents. Patients must have: Documented HIV infection. PCP. No more than 36 hours of prior primary therapy for confirmed or presumed PCP. Prior Medication: Allowed: Up to 35 hours of primary therapy for confirmed or presumed PCP. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Demonstrated intolerance to steroids. Requirement for steroids at greater than physiological doses for other medical conditions.

Ages Eligible for Study
-----------------
Minimum Age: 28 Days
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Methylprednisolone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pneumonia, Pneumocystis carinii, Acquired Immunodeficiency Syndrome, Methylprednisolone
The ADRB3 Receptor in Pregnancy

Study Overview
=================
Brief Summary
-----------------
The primary overall objective of this study is to characterize the levels of and compare levels of the ADRB3 receptor in human non-pregnant myometrium, pregnant myometrium at different time points in pregnancy, in normal and dysfunctional labor and also to measure levels and expression of these receptors in placental arteries at different maturation statuses of placenta and in pre-eclampsia/hypertension

Official Title
-----------------
The ADRB3 Adrenergic Receptor - a Possible New Target for Controlling Pre-eclampsia and Hypertension in Pregnancy and Uterine Contractions in Non-pregnant and Pregnant Myometrium

Conditions
-----------------
Pregnancy Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women undergoing cesarian section Exclusion Criteria: Interkurrent diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women with preeclampsia<br>Women delivered by cesarian section and with preeclampsia | |
| Women with dysfunctional labor<br>Women delivered with cesarian section due to dtsfunctional labor | |
| Women with cesarian section due to maternal request<br>Women with cesarian section due to maternal request | |
| Women with preamture labor<br>Women with pemature labor undergoing cesarian section | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| characterization of the levels of the ADRB3 receptor in human pregnant myometrium |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
arterial contractility, Uterine contractility